Wealth Enhancement Advisory Services LLC Has $7.26 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Wealth Enhancement Advisory Services LLC decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 42.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,559 shares of the medical research company’s stock after selling 68,643 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Edwards Lifesciences were worth $7,255,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $28,000. True Wealth Design LLC grew its holdings in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares during the period. NewSquare Capital LLC increased its stake in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in shares of Edwards Lifesciences during the third quarter valued at about $30,000. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 29th. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company set a $100.00 price target on shares of Edwards Lifesciences in a research note on Thursday, December 18th. Finally, Citigroup reiterated a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $83.70 on Friday. The company’s fifty day moving average price is $84.99 and its 200-day moving average price is $80.83. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm has a market capitalization of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.19 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company earned $0.67 EPS. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president owned 38,970 shares of the company’s stock, valued at $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.